Dupilumab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis
Conditions
Atopic Dermatitis, Sleep Disturbance
Trial Timeline
Aug 12, 2024 → Dec 1, 2025
NCT ID
NCT05042258About Dupilumab
Dupilumab is a approved stage product being developed by Regeneron Pharmaceuticals for Atopic Dermatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05042258. Target conditions include Atopic Dermatitis, Sleep Disturbance.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
20 competing products in Atopic Dermatitis